Reviva Pharmaceuticals Hldg Inc (RVPH)

$0.23 +0.02 (8.29%)
Market Cap 24.70M
Revenue (ttm) 0.00
Net Income (ttm) -29.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,465,130
Avg Vol 5,119,904
Day's Range N/A - N/A
Shares Out 115.06M
Stochastic %K 22%
Beta 0.06
Analysts Strong Sell
Price Target $4.81

Company Profile

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 501 8881
Fax: 408 904 6270
Address:
10080 N. Wolfe Road, Suite SW3-200, Cupertino, United States
Whiskeyunderthebed
Whiskeyunderthebed Mar. 2 at 7:38 PM
$RVPH Yea they are holding Iranian Rials-what's your point-it's worthless.
0 · Reply
GreenMachine38
GreenMachine38 Mar. 2 at 7:37 PM
$RVPH Bhat could have the cure for cancer and couldn’t get it to market
0 · Reply
roguebard1
roguebard1 Mar. 2 at 4:28 PM
$RVPH Bottom in?
2 · Reply
K_VB
K_VB Mar. 1 at 5:46 PM
$RVPH RVPH added to DelveInsight’s 2025 Pulmonary Fibrosis Pipeline. Brilaroxazine listed with EU IPF patent, global IP protection, and FDA Orphan Drug Designation, positioning Reviva as a CNS + IPF dual‑platform alongside major players like BI, BMS, GSK, Pliant
1 · Reply
Anomalies
Anomalies Mar. 1 at 3:28 PM
$RVPH more red incoming!?
0 · Reply
UgoGreg
UgoGreg Feb. 28 at 3:51 PM
$RVPH https://youtu.be/ygBN8MilTyc
0 · Reply
biovaluable
biovaluable Feb. 28 at 11:49 AM
$RVPH war is comming
0 · Reply
roguebard1
roguebard1 Feb. 28 at 5:24 AM
$RVPH research what you're investing in. Get to know it. When you're sold on it, buy they stock. https://www.youtube.com/watch?v=a0ZZjPEXbbU
0 · Reply
Pga27bam
Pga27bam Feb. 27 at 8:57 PM
$RVPH 4% of this stock held by insiders
1 · Reply
biovaluable
biovaluable Feb. 26 at 10:49 PM
$RVPH rs
0 · Reply
Latest News on RVPH
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Dec 29, 2025, 8:00 AM EST - 2 months ago

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Dec 23, 2025, 9:26 AM EST - 2 months ago

FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Dec 23, 2025, 8:00 AM EST - 2 months ago

Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 13, 2025, 4:05 PM EST - 3 months ago

Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Oct 7, 2025, 4:08 PM EDT - 5 months ago

Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners

Top 3 Health Care Stocks That May Explode In September

Sep 19, 2025, 7:01 AM EDT - 5 months ago

Top 3 Health Care Stocks That May Explode In September

ATYR BSX

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Sep 18, 2025, 9:26 PM EDT - 5 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Sep 18, 2025, 4:05 PM EDT - 5 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 14, 2025, 4:25 PM EDT - 7 months ago

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Jun 26, 2025, 8:40 AM EDT - 8 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Jun 2, 2025, 7:00 AM EDT - 9 months ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025, 4:05 PM EDT - 10 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Mar 30, 2025, 11:30 AM EDT - 1 year ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Jan 30, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Jan 7, 2025, 8:00 AM EST - 1 year ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

Reviva Announces Proposed Public Offering

Dec 16, 2024, 5:18 PM EST - 1 year ago

Reviva Announces Proposed Public Offering

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Dec 11, 2024, 3:37 PM EST - 1 year ago

Reviva Pharmaceuticals: Upcoming Events May Generate Excitement, But Cash Is Low

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 5:25 PM EST - 1 year ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the UBS Global Healthcare Conference

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:30 AM EDT - 1 year ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Aug 21, 2024, 6:00 AM EDT - 1 year ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 29, 2024, 4:45 PM EDT - 1 year ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 28, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Reviva to Participate in the BIO International Convention

May 21, 2024, 8:00 AM EDT - 1 year ago

Reviva to Participate in the BIO International Convention

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

May 15, 2024, 8:00 AM EDT - 1 year ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 14, 2024, 8:00 AM EDT - 1 year ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

May 9, 2024, 8:00 AM EDT - 1 year ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Apr 15, 2024, 8:30 AM EDT - 2 years ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Apr 15, 2024, 8:05 AM EDT - 2 years ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Mar 26, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Reviva to Present at the UBS Virtual CNS Day

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Reviva to Present at the UBS Virtual CNS Day

Reviva to Present at the 36th Annual ROTH Conference

Mar 7, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at the 36th Annual ROTH Conference

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 20, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Feb 6, 2024, 8:00 AM EST - 2 years ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Jan 25, 2024, 8:00 AM EST - 2 years ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Jan 10, 2024, 8:00 AM EST - 2 years ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Jan 4, 2024, 8:00 AM EST - 2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Dec 11, 2023, 8:00 AM EST - 2 years ago

Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Nov 30, 2023, 4:05 PM EST - 2 years ago

Reviva Pharmaceuticals to Participate in The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Nov 20, 2023, 4:05 PM EST - 2 years ago

Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Whiskeyunderthebed
Whiskeyunderthebed Mar. 2 at 7:38 PM
$RVPH Yea they are holding Iranian Rials-what's your point-it's worthless.
0 · Reply
GreenMachine38
GreenMachine38 Mar. 2 at 7:37 PM
$RVPH Bhat could have the cure for cancer and couldn’t get it to market
0 · Reply
roguebard1
roguebard1 Mar. 2 at 4:28 PM
$RVPH Bottom in?
2 · Reply
K_VB
K_VB Mar. 1 at 5:46 PM
$RVPH RVPH added to DelveInsight’s 2025 Pulmonary Fibrosis Pipeline. Brilaroxazine listed with EU IPF patent, global IP protection, and FDA Orphan Drug Designation, positioning Reviva as a CNS + IPF dual‑platform alongside major players like BI, BMS, GSK, Pliant
1 · Reply
Anomalies
Anomalies Mar. 1 at 3:28 PM
$RVPH more red incoming!?
0 · Reply
UgoGreg
UgoGreg Feb. 28 at 3:51 PM
$RVPH https://youtu.be/ygBN8MilTyc
0 · Reply
biovaluable
biovaluable Feb. 28 at 11:49 AM
$RVPH war is comming
0 · Reply
roguebard1
roguebard1 Feb. 28 at 5:24 AM
$RVPH research what you're investing in. Get to know it. When you're sold on it, buy they stock. https://www.youtube.com/watch?v=a0ZZjPEXbbU
0 · Reply
Pga27bam
Pga27bam Feb. 27 at 8:57 PM
$RVPH 4% of this stock held by insiders
1 · Reply
biovaluable
biovaluable Feb. 26 at 10:49 PM
$RVPH rs
0 · Reply
History101
History101 Feb. 26 at 9:39 PM
$RVPH my 1 share at 29 cents is now down over 23%. This was an $8 stock in 2023.
0 · Reply
BadensBester
BadensBester Feb. 26 at 9:05 PM
$RVPH i bought 10k shares more, fuck off
5 · Reply
Arce75
Arce75 Feb. 26 at 9:03 PM
$RVPH 9,34% down, under 0,20, any more bad news? Only Banana can save this
1 · Reply
Pga27bam
Pga27bam Feb. 26 at 2:49 PM
$RVPH Had 40k shares and sold 10k of them couple weeks ago. I am very close to selling another 20k shares. This has been a joke.
3 · Reply
DonkeyPuncherDude
DonkeyPuncherDude Feb. 25 at 11:45 PM
$RVPH If you are still holding from 1-3yrs ago, you need mental help.
0 · Reply
ONLYPHARMS
ONLYPHARMS Feb. 25 at 11:37 PM
$RVPH has reverse split been voted on by shareholders?
2 · Reply
Vito99
Vito99 Feb. 25 at 7:38 PM
$RVPH Why hasn’t he been participating in conferences for over a month
3 · Reply
Tonyromo9
Tonyromo9 Feb. 25 at 4:19 PM
$RVPH
0 · Reply
GreenMachine38
GreenMachine38 Feb. 24 at 9:57 PM
$RVPH I’m gonna load the boat once price is back at these levels after the reverse split
6 · Reply
History101
History101 Feb. 23 at 11:30 PM
$RVPH i was excited when the ph3 results were announced in late October, 2023. if you had told me that in late Feb 2026 RVPH would have made ZERO progress since, i would not have believed it. so sad for patients afflicted with schizo.
0 · Reply
History101
History101 Feb. 23 at 10:21 PM
$RVPH right now i think i would like to pick a name out of the phone book to be our CEO rather than what we have now...
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 2:11 PM
$RVPH RSI: 30.00, MACD: -0.0299 Vol: 0.02, MA20: 0.28, MA50: 0.37 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply